Suppr超能文献

GOLT1A-KISS1 融合与腺样囊性癌的转移有关。

GOLT1A-KISS1 fusion is associated with metastasis in adenoid cystic carcinomas.

机构信息

National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan, 430068, China.

National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan, 430068, China.

出版信息

Biochem Biophys Res Commun. 2020 May 21;526(1):70-77. doi: 10.1016/j.bbrc.2020.03.005. Epub 2020 Mar 17.

Abstract

Genetic alterations can drive carcinogenesis. Numerous studies have shown that gene fusion is associated with cancer progression and could provide valuable biomarkers for clinical diagnosis or targets for cancer therapy. Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, characterized by frequent local recurrence and high rates of distant metastasis, ultimately resulting in low survival rates. Owing to the lack of effective therapeutic targets and limited biomarkers for diagnosis, a deeper understanding of the molecular basis of ACC is urgently needed. Here, we show that gene fusion is associated with ACC metastasis. We identified a metastasis suppressor KISS1 fused with a close-by gene, GOLT1A, in highly metastatic ACC cell lines and human specimens. Such fusion blocks KISS1 translation, but not transcription, by introducing 5' upstream open reading frames (uORFs) in the GOLT1A-KISS1 fusion transcript. Deletion of these uORFs rescued KISS1 expression and reduced invasion and migration of metastatic ACC cells. We also detected GOLT1A-KISS1 fusion transcripts in other types of highly metastatic cancer cell lines. Taken together, our results highlight the significance of this novel GOLT1A-KISS1 gene fusion in tumor metastasis and provide a valuable biomarker for clinical diagnosis and future therapeutic targeting of ACC.

摘要

遗传改变可驱动致癌作用。大量研究表明,基因融合与癌症进展相关,并可为临床诊断提供有价值的生物标志物或癌症治疗靶点。腺样囊性癌(adenoid cystic carcinoma,ACC)是一种罕见的腺癌,其特征为频繁局部复发和远处转移率高,最终导致生存率低。由于缺乏有效的治疗靶点和有限的诊断生物标志物,因此迫切需要更深入地了解 ACC 的分子基础。在这里,我们表明基因融合与 ACC 的转移有关。我们在高转移性 ACC 细胞系和人类标本中鉴定到了与 GOLT1A 融合的转移抑制基因 KISS1。这种融合通过在 GOLT1A-KISS1 融合转录本中引入 5' 上游开放阅读框(uORFs)来阻断 KISS1 的翻译,但不阻断转录。删除这些 uORFs 可挽救 KISS1 的表达,并降低转移性 ACC 细胞的侵袭和迁移。我们还在其他类型的高转移性癌细胞系中检测到了 GOLT1A-KISS1 融合转录本。总之,我们的研究结果强调了这种新型 GOLT1A-KISS1 基因融合在肿瘤转移中的重要性,并为 ACC 的临床诊断和未来的治疗靶向提供了有价值的生物标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验